{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:43:35Z","timestamp":1791420215150,"version":"4.3.3"},"reference-count":43,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:p>OBJECTIVE. Despite the promising preliminary results observed in extremely low birth weight (ELBW) populations, the use of fluconazole to prevent fungal colonization and infection in preterm neonates in the NICU is still an open question and not yet recommended as a standard of care. We have reviewed our 6-year series to assess the effectiveness and safety of this form of prophylaxis.<\/jats:p><jats:p>METHODS. This retrospective study consisted of 465 neonates who weighed &amp;lt;1500 g at birth and were admitted to our NICU in the period 1998\u20132003. Those who were born between 1998 and 2000 and did not receive fluconazole prophylaxis (group A, n = 240) were compared with those who were born between 2001 and 2003 and treated with fluconazole until the 30th day of life (45th for neonates &amp;lt;1000 g at birth; group B, n = 225). Weekly surveillance cultures were obtained from all patients. Incidence of fungal colonization, incidence of systemic fungal infection (SFI), rate of progression from colonization to infection, and mortality rates attributable to fungi were calculated for both groups and separately for neonates who were &amp;lt;1000 g (ELBW) and were 1001 to 1500 g (NE-VLBW) at birth.<\/jats:p><jats:p>RESULTS. Overall fungal colonization was significantly lower in group B (24.0%) than in group A (43.8%; relative risk [RR]: 0.406; 95% confidence interval [CI]: 0.273\u20130.605). The same was true of neonates with colonization in multiple sites (2.6% vs 5.8%) and of those with colonization from high-risk sites (5.8% vs 19.2%). SFI incidence was significantly lower in group B (10 of 225 cases; 4.4%) than in group A (40 of 240 cases; 16.7%; RR: 0.233; 95% CI: 0.113\u20130.447). Reduction of both colonization and SFI in group B was greater in the ELBW neonates and also significant in the NE-VLBW neonates. Rate of progression from colonization to infection was significantly lower in group B (0.17 vs 0.38; RR: 0.369; 95% CI: 0.159\u20130.815). Crude mortality rate attributable to Candida species was 1.7% (4 of 240) in group A vs 0% (0 of 225) in group B. Overall mortality rate (any cause before hospital discharge) was similar in the two groups (11.2% vs 10.6%), but in colonized infants (n = 159), it was significantly lower in group B (3.7% vs 18.1%; RR: 0.174; 95% CI: 0.039\u20130.778). The incidence of natively fluconazole-resistant fungal species did not increase over the years, and patterns of sensitivity to fluconazole remained the same. No adverse reaction related to fluconazole occurred.<\/jats:p><jats:p>CONCLUSIONS. Prophylactic fluconazole significantly reduces the incidence of colonization and systemic infection by Candida species in both ELBW and NE-VLBW neonates and decreases the rates of progression from initial colonization to massive colonization and to systemic infection. All VLBW neonates may benefit from fluconazole prophylaxis.<\/jats:p>","DOI":"10.1542\/peds.2004-2227","type":"journal-article","created":{"date-parts":[[2005,12,3]],"date-time":"2005-12-03T01:12:49Z","timestamp":1133572369000},"page":"e22-e32","source":"Crossref","is-referenced-by-count":130,"title":["Prophylactic Fluconazole Is Effective in Preventing Fungal Colonization and Fungal Systemic Infections in Preterm Neonates: A Single-Center, 6-Year, Retrospective Cohort Study"],"prefix":"10.1542","volume":"117","author":[{"given":"Paolo","family":"Manzoni","sequence":"first","affiliation":[{"name":"Neonatology and Hospital NICU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Arisio","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mostert","sequence":"additional","affiliation":[{"name":"Pediatric Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MariaLisa","family":"Leonessa","sequence":"additional","affiliation":[{"name":"Neonatology and Hospital NICU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Farina","sequence":"additional","affiliation":[{"name":"Neonatology and Hospital NICU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Agnese","family":"Latino","sequence":"additional","affiliation":[{"name":"Clinical Pathology and Microbiology, Azienda Ospedaliera Regina Margherita-S. Anna, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Gomirato","sequence":"additional","affiliation":[{"name":"Neonatology and Hospital NICU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,1,1]]},"reference":[{"key":"2021120819443246700_R1","doi-asserted-by":"crossref","unstructured":"Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics.\u20082002;109:34\u201339","DOI":"10.1542\/peds.109.1.34"},{"key":"2021120819443246700_R2","doi-asserted-by":"crossref","unstructured":"Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics.\u20082002;110:285\u2013291","DOI":"10.1542\/peds.110.2.285"},{"key":"2021120819443246700_R3","doi-asserted-by":"crossref","unstructured":"Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J.\u20081998;17:504\u2013508","DOI":"10.1097\/00006454-199806000-00014"},{"key":"2021120819443246700_R4","doi-asserted-by":"crossref","unstructured":"Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J.\u20082000;19:319\u2013324","DOI":"10.1097\/00006454-200004000-00011"},{"key":"2021120819443246700_R5","unstructured":"Karlowicz MG, Rowen JL, Barnes-Eley ML, et al. The role of birth weight and gestational age in distinguishing extremely low birth weight infants at high risk of developing candidemia from infants at low risk: a multicenter study. Pediatr Res.\u20082002;51:301A"},{"key":"2021120819443246700_R6","doi-asserted-by":"crossref","unstructured":"Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the very low birth weight infant. Pediatrics.\u20081986;78:225\u2013232","DOI":"10.1542\/peds.78.2.225"},{"key":"2021120819443246700_R7","doi-asserted-by":"crossref","unstructured":"Huang YC, Li CC, Lin TY. Association of fungal colonization and invasive disease in very low birth weight infants. Pediatr Infect Dis J.\u20081998;17:819\u2013822","DOI":"10.1097\/00006454-199809000-00014"},{"key":"2021120819443246700_R8","doi-asserted-by":"crossref","unstructured":"Pappu-Katikaneni LD, Rao KP, Banister E. Gastrointestinal colonization with yeast species and Candida septicemia in very low birth weight infants. Mycoses.\u20081990;33:20\u201323","DOI":"10.1111\/myc.1990.33.1.20"},{"key":"2021120819443246700_R9","doi-asserted-by":"crossref","unstructured":"Rowen JL, Rench MA, Kozinetz CA, Adams JM Jr, Baker CJ. Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates. J Pediatr.\u20081994;124:789\u2013784","DOI":"10.1016\/S0022-3476(05)81375-7"},{"key":"2021120819443246700_R10","doi-asserted-by":"crossref","unstructured":"Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J.\u20082001;20:1119\u20131124","DOI":"10.1097\/00006454-200112000-00005"},{"key":"2021120819443246700_R11","doi-asserted-by":"crossref","unstructured":"Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med.\u20082001;345:1660\u20131666","DOI":"10.1056\/NEJMoa010494"},{"key":"2021120819443246700_R12","doi-asserted-by":"crossref","unstructured":"Benjamin DK Jr, Ross K, McKinney RE Jr, Benjamin DK, Auten R, Fisher RG. When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics.\u20082000;106:712\u2013718","DOI":"10.1542\/peds.106.4.712"},{"key":"2021120819443246700_R13","doi-asserted-by":"crossref","unstructured":"Benjamin DK, DeLong ER, Steinbach WJ, Cotton CM, Walsh TJ, Clark RH. Empirical therapy for neonatal candidemia in VLBW infants. Pediatrics.\u20082003;112:543\u2013547","DOI":"10.1542\/peds.112.3.543"},{"key":"2021120819443246700_R14","doi-asserted-by":"crossref","unstructured":"Guida JD, Kunig AM, Leef KH, McKenzie SE, Paul DA. Platelet count and sepsis in VLBW neonates: is there an organism-specific response?Pediatrics.\u20082003;111:1411\u20131415","DOI":"10.1542\/peds.111.6.1411"},{"key":"2021120819443246700_R15","doi-asserted-by":"crossref","unstructured":"Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of Candidiasis. Clin Infect Dis.\u20082004;38:161\u2013189","DOI":"10.1086\/380796"},{"key":"2021120819443246700_R16","doi-asserted-by":"crossref","unstructured":"Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents.\u20082000;15:83\u201390","DOI":"10.1016\/S0924-8579(00)00147-3"},{"key":"2021120819443246700_R17","doi-asserted-by":"crossref","unstructured":"Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis.\u20082002;34:7\u201314","DOI":"10.1086\/323335"},{"key":"2021120819443246700_R18","unstructured":"Manzoni P, Pedicino R, Stolfi I, et al. Criteria for the diagnosis of systemic fungal infections in newborns: a report from the Task Force on neonatal fungal infections of the GSIN [in Italian]. Pediatr Med Chir.\u20082004;26:89\u201395"},{"key":"2021120819443246700_R19","doi-asserted-by":"crossref","unstructured":"Gotzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev. 2002;(2):CD000026","DOI":"10.1002\/14651858.CD000026"},{"key":"2021120819443246700_R20","doi-asserted-by":"crossref","unstructured":"Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect.\u20082004;10(suppl 1):86\u201395","DOI":"10.1111\/j.1470-9465.2004.00847.x"},{"key":"2021120819443246700_R21","doi-asserted-by":"crossref","unstructured":"Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg.\u20082001;233:542\u2013548","DOI":"10.1097\/00000658-200104000-00010"},{"key":"2021120819443246700_R22","doi-asserted-by":"crossref","unstructured":"Laverdiere M, Rotstein C, Bow EJ, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother.\u20082000;46:1001\u20131008","DOI":"10.1093\/jac\/46.6.1001"},{"key":"2021120819443246700_R23","doi-asserted-by":"crossref","unstructured":"Ninane J, Multicentre Study Group. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with haematological or oncological malignancies. Eur J Clin Microbiol Infect Dis.\u20081994;13:30\u201337","DOI":"10.1007\/BF01974614"},{"key":"2021120819443246700_R24","doi-asserted-by":"crossref","unstructured":"Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics.\u20082001;107:293\u2013298","DOI":"10.1542\/peds.107.2.293"},{"key":"2021120819443246700_R25","doi-asserted-by":"crossref","unstructured":"Sims ME, Yoo Y, You H, Salminen C, Walther FJ. Prophylactic oral nystatin and fungal infections in very-low-birth-weight infants. Am J Perinatol.\u20081988;5:33\u201336","DOI":"10.1055\/s-2007-999649"},{"key":"2021120819443246700_R26","doi-asserted-by":"crossref","unstructured":"Austin NC, Darlow B. Prophylactic oral anti-fungal agents to prevent systemic Candida infection in preterm infants. Cochrane Database Syst Rev. 2004;(1):CD003478","DOI":"10.1002\/14651858.CD003478.pub2"},{"key":"2021120819443246700_R27","doi-asserted-by":"crossref","unstructured":"Wainer S, Cooper PA, Funk E, Bental RY, Sandler DA, Patel J. Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J.\u20081992;11:713\u2013716","DOI":"10.1097\/00006454-199209000-00008"},{"key":"2021120819443246700_R28","doi-asserted-by":"crossref","unstructured":"Neely MN, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics.\u20082001;107:404\u2013405","DOI":"10.1542\/peds.107.2.404"},{"key":"2021120819443246700_R29","doi-asserted-by":"crossref","unstructured":"McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2004;(1):CD003850","DOI":"10.1002\/14651858.CD003850.pub2"},{"key":"2021120819443246700_R30","unstructured":"Mouzinho A, Rosenfeld CR, Sanchez PJ Risser R. Revised reference ranges for circulating neutrophils in very low birth weight neonates. Pediatrics.\u20081994;94:76\u201382"},{"key":"2021120819443246700_R31","doi-asserted-by":"crossref","unstructured":"Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med.\u20081997;23:23\u201330","DOI":"10.1007\/s001340050286"},{"key":"2021120819443246700_R32","doi-asserted-by":"crossref","unstructured":"Karlowicz MG, Hashimoto LN, Kelly RE Jr, Buescher ES. Should central venous catheters be removed as soon as candidemia is detected in neonates?Pediatrics.\u20082000;106(5). Available at: www.pediatrics.org\/cgi\/content\/full\/106\/5\/e63","DOI":"10.1542\/peds.106.5.e63"},{"key":"2021120819443246700_R33","doi-asserted-by":"crossref","unstructured":"Huttova M, Filka J, Kurak J, Kralinsky K, Krcmery V. Candida fungaemia in neonates treated with fluconazole. Pediatr Infect Dis J.\u20081998;17:1112\u20131116","DOI":"10.1097\/00006454-199811000-00010"},{"key":"2021120819443246700_R34","doi-asserted-by":"crossref","unstructured":"Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother.\u20081999;43:1955\u20131960","DOI":"10.1128\/AAC.43.8.1955"},{"key":"2021120819443246700_R35","doi-asserted-by":"crossref","unstructured":"Wenzl TG, Schefels J, Hornchen H, Skopnik H. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr.\u20081998;157:661\u2013662","DOI":"10.1007\/s004310050906"},{"key":"2021120819443246700_R36","doi-asserted-by":"crossref","unstructured":"Brammer KW, Coates PE. Pharmacokinetics of fluconazole in paediatric patients. Eur J Clin Microbiol Infect Dis.\u20081994;13:325\u2013329","DOI":"10.1007\/BF01974613"},{"key":"2021120819443246700_R37","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997"},{"key":"2021120819443246700_R38","unstructured":"Slotman GJ, Saphiro R, Moffa SM. Fungal sepsis: multisite colonization versus fungemia. Am Surg.\u20081994;60:107\u2013113"},{"key":"2021120819443246700_R39","doi-asserted-by":"crossref","unstructured":"Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Am Surg.\u20081994;6:751\u2013758","DOI":"10.1097\/00000658-199412000-00008"},{"key":"2021120819443246700_R40","doi-asserted-by":"crossref","unstructured":"Nahata MC, Tallian KB, Force RW. Pharmacokinetics of fluconazole in young infants. Eur J Drug Metab Pharmacokinet.\u20081999;24:155\u2013157","DOI":"10.1007\/BF03190361"},{"key":"2021120819443246700_R41","doi-asserted-by":"crossref","unstructured":"Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect.\u20082002;50:56\u201365","DOI":"10.1053\/jhin.2001.1131"},{"key":"2021120819443246700_R42","unstructured":"Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossmann LB. Sensitivities of Fungal Isolates in High-Risk Preterm Infants Exposed to Fluconazole Prophylaxis in a Neonatal Intensive Care Unit over a 5-Year Period. Poster presented at: the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC; November 2004 (in press)"},{"key":"2021120819443246700_R43","unstructured":"Kaufman D, Dover CM, Reynolds SE, et al. Sensitivity of Candida isolates in high-risk preterm infants exposed to fluconazole prophylaxis in a neonatal intensive care unit over a 6-year period. Pediatric Academic Societies.\u20082005;57:647"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/1\/e22\/1010519\/zpe00106000e22.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/1\/e22\/1010519\/zpe00106000e22.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T18:41:16Z","timestamp":1683312076000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/1\/e22\/67963\/Prophylactic-Fluconazole-Is-Effective-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2006,1,1]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2227","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}